| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ... Science translational medicine 9 (399), eaaa0984, 2017 | 1488 | 2017 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 736 | 2019 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 678 | 2015 |
| Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and … H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash, TE Donegan, ... Journal of clinical oncology 29 (3), 330, 2011 | 677 | 2011 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 548 | 2014 |
| Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment S Müller, G Kohanbash, SJ Liu, B Alvarado, D Carrera, A Bhaduri, ... Genome biology 18, 1-14, 2017 | 540 | 2017 |
| Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Science translational medicine 7 (275), 275ra22-275ra22, 2015 | 491 | 2015 |
| COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells M Fujita, G Kohanbash, W Fellows-Mayle, RL Hamilton, Y Komohara, ... Cancer research 71 (7), 2664-2674, 2011 | 413 | 2011 |
| Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas G Kohanbash, DA Carrera, S Shrivastav, BJ Ahn, N Jahan, T Mazor, ... The Journal of clinical investigation 127 (4), 1425-1437, 2017 | 362 | 2017 |
| SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma JH Choe, PB Watchmaker, MS Simic, RD Gilbert, AW Li, NA Krasnow, ... Science translational medicine 13 (591), eabe7378, 2021 | 265 | 2021 |
| Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models X Zhu, F Nishimura, K Sasaki, M Fujita, JE Dusak, J Eguchi, ... Journal of translational medicine 5, 1-15, 2007 | 223 | 2007 |
| STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment T Ohkuri, A Ghosh, A Kosaka, J Zhu, M Ikeura, M David, SC Watkins, ... Cancer immunology research 2 (12), 1199-1208, 2014 | 221 | 2014 |
| Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and … IF Pollack, RI Jakacki, LH Butterfield, RL Hamilton, A Panigrahy, ... Journal of Clinical Oncology 32 (19), 2050, 2014 | 210 | 2014 |
| Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy ZS Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ... Journal of Experimental Medicine 215 (1), 141-157, 2018 | 208 | 2018 |
| GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α G Kohanbash, K McKaveney, M Sakaki, R Ueda, AH Mintz, N Amankulor, ... Cancer research 73 (21), 6413-6423, 2013 | 205 | 2013 |
| Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 R Ueda, G Kohanbash, K Sasaki, M Fujita, X Zhu, ER Kastenhuber, ... Proceedings of the National Academy of Sciences 106 (26), 10746-10751, 2009 | 205 | 2009 |
| Immunotherapeutic approaches for glioma H Okada, G Kohanbash, X Zhu, ER Kastenhuber, A Hoji, R Ueda, M Fujita Critical Reviews™ in Immunology 29 (1), 2009 | 199 | 2009 |
| Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy X Zhu, M Fujita, LA Snyder, H Okada Journal of neuro-oncology 104, 83-92, 2011 | 197 | 2011 |
| Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly … T Tatsumi, J Huang, WE Gooding, A Gambotto, PD Robbins, ... Cancer research 63 (19), 6378-6386, 2003 | 188 | 2003 |
| Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell–based therapeutics JG Zhang, J Eguchi, CA Kruse, GG Gomez, H Fakhrai, S Schroter, W Ma, ... Clinical Cancer Research 13 (2), 566-575, 2007 | 185 | 2007 |
